Needham & Company Reiterates a 'Buy' on Solta Medical (SLTM); Revenue Grows for Eighth Consecutive Quarter
Tweet
Share
E-mailGet Alerts SLTM Hot Sheet
Price: $2.92 --0%
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 17
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 17
Join SI Premium – FREE
Needham & Company reiterates a 'Buy' on Solta Medical (NASDAQ: SLTM) price target of $5.00.
Needham analyst says, "SLTM continues the general trend observed in our aesthetic technology universe with continued moderate growth as the sector recovers from the depths of the recession. We think continued growth in the disposables is encouraging and the fact that disposable revenue took only a brief small dip due to the recession squares with anecdotal evidence we have gathered regarding overall procedure trends. With the LipoSonix 2G system now approved and the acquisition now closed, we think SLTM has a promising new avenue for growth."
"Changes to our 2012 revenue estimates assume 10% organic growth plus $18 M in revenue from LipoSonix. This higher revenue adds only a penny a share to EPS as we expect LipoSonix to be a drag on margins early in the year, becoming accretive in 4Q12."
For more ratings news on Solta Medical click here and for the rating history of Solta Medical click here.
Shares of Solta Medical closed at $2.21 yesterday.
Needham analyst says, "SLTM continues the general trend observed in our aesthetic technology universe with continued moderate growth as the sector recovers from the depths of the recession. We think continued growth in the disposables is encouraging and the fact that disposable revenue took only a brief small dip due to the recession squares with anecdotal evidence we have gathered regarding overall procedure trends. With the LipoSonix 2G system now approved and the acquisition now closed, we think SLTM has a promising new avenue for growth."
"Changes to our 2012 revenue estimates assume 10% organic growth plus $18 M in revenue from LipoSonix. This higher revenue adds only a penny a share to EPS as we expect LipoSonix to be a drag on margins early in the year, becoming accretive in 4Q12."
For more ratings news on Solta Medical click here and for the rating history of Solta Medical click here.
Shares of Solta Medical closed at $2.21 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Starts Pulse Biosciences (PLSE) at Buy
- Clear Street Downgrades Kinetik Holdings, Inc. (KNTK) to Hold Citing Valuation
- Intuit (INTU) PT Lowered to $430 at Mizuho
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
